Full Press Release Details
Pharmaceuticals, Inc.
Announces $5 Million Registered Direct Offering of Common Stock
YORK, NY, June 4, 2015 - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE
MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced
cancers, announced today that it entered into subscription agreements with certain investors to sell approximately $5 million
of its common stock in a registered direct offering. Under the terms of the subscription agreements, the Company will issue an
aggregate of 1,923,078 shares of the Company's common stock at a purchase price of $2.60 per share. The offering is expected
to close on or about June 10, 2015, subject to the satisfaction of customary closing conditions. This financing was led by investor
anticipates using the net proceeds for general corporate purposes, including capital expenditures, the advancement of our product
candidates in clinical trials, such as Iomab -B and Actimab-A, preclinical trials, to support licensing activities, and
to meet working capital needs.
& Company (UK) Ltd. acted as the sole placement agent with respect to the offering.
securities were offered pursuant to the Company's effective shelf registration statement previously filed with the Securities
and Exchange Commission on Form S-3. A prospectus supplement relating to the offering will be filed with the SEC and will be available
free of charge on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained
from Laidlaw & Company (UK) Ltd. 546 Fifth Avenue, New York, NY 10036, Attn: Syndicate Department, telephone: 212-953-4900,
email: syndicate@laidlawltd.com, or from the above-mentioned SEC website.
press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
Actinium Pharmaceuticals
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals
in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing
patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single,
pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary
endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase
1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Statement for Actinium Pharmaceuticals, Inc.
news release contains "forward-looking statements". These statements are based on management's current expectations
and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.
The forward-looking statements may include statements regarding product development, product potential or financial performance.
No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium undertakes
no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SVP, Finance and Corporate Development
Pharmaceuticals, Inc.